©The Author(s) 2026.
World J Hepatol. Feb 27, 2026; 18(2): 114481
Published online Feb 27, 2026. doi: 10.4254/wjh.v18.i2.114481
Published online Feb 27, 2026. doi: 10.4254/wjh.v18.i2.114481
Table 1 Autoimmune hepatitis cohort characteristics, n (%)
| Characteristic | Total (n = 15187) | |
| Individuals not on IS (n = 10081) | Individuals on IS (n = 5106) | |
| Age | ||
| 18-29 | 780 (7.7) | 572 (11.2) |
| 30-39 | 1003 (9.9) | 620 (12.1) |
| 40-49 | 1392 (13.8) | 685 (13.4) |
| 50-59 | 1922 (19.1) | 869 (17.0) |
| 60 + | 4976 (49.4) | 2358 (46.2) |
| Sex | ||
| Female | 7176 (71.2) | 3609 (70.7) |
| Male | 2681 (26.6) | 1275 (25.0) |
| Unknown | 224 (2.2) | 222 (4.3) |
| Race/ethnicity | ||
| White | 6898 (68.4) | 3344 (65.5) |
| Black | 1479 (14.7) | 921 (18.0) |
| Hispanic | 640 (6.3) | 396 (7.8) |
| Asian | 453 (4.5) | 142 (2.8) |
| Other/unknown | 611 (6.1) | 303 (5.9) |
| Height (in.) | 65.5 | 65.8 |
| Weight (lbs.) | 180.51 | 177.4 |
| BMI | 30.24 | 29.5 |
| Region | ||
| Northeast | 432 (4.3) | 252 (4.9) |
| Midwest | 1558 (15.5) | 1034 (20.3) |
| South | 2026 (20.1) | 1248 (24.4) |
| West | 1049 (10.4) | 779 (15.3) |
| Other/unlisted | 5016 (49.8) | 1793 (35.1) |
| Comorbid conditions | ||
| CCI | 5.16 | 5.17 |
| Diabetes | 1072 (10.6) | 635 (12.4) |
| MI | 369 (3.7) | 181 (3.5) |
| CHF | 533 (5.3) | 307 (6.0) |
| PVD | 568 (5.6) | 302 (5.9) |
| Chronic renal disease | 512 (5.1) | 461 (9.0) |
| Chronic pulmonary disease | 1406 (13.9) | 883 (17.3) |
| Cirrhosis | ||
| Compensated cirrhosis | 284 (2.8) | 159 (3.1) |
| Decompensated cirrhosis | 143 (1.4) | 74 (1.4) |
| Complications of cirrhosis | ||
| Hepatic encephalopathy | < 201 | < 201 |
| Esophageal varices | 33 (0.3) | < 201 (0.5) |
| Ascites/pleural effusion | 76 (0.8) | 27 (0.5) |
| Hepatorenal syndrome | < 201 | < 201 |
| Hepatocellular carcinoma | 361 (3.6) | 312 (6.1) |
| IS used | ||
| Azathioprine | 2112 (41.36) | |
| Prednisone | 2977 (58.3) | |
| Budesonide | 720 (14.1) | |
| Mycophenolate mofetil | 208 (4.1) | |
| Tacrolimus | 940 (18.4) | |
| Cyclosporine | 200 (3.9) | |
| Laboratory tests | ||
| MELD 3.0 score | 13.8 | 13.8 |
| Sodium (mmol/L) | 135.8 | 135.8 |
| Creatinine (mg/dL) | 1.2 | 1.2 |
| Bilirubin (mg/dL) | 12 | 2.2 |
| INR | 1.3 | 1.3 |
| Albumin (g/dL) | 3.2 | 3.3 |
| AST (U/L) | 112.7 | 95.8 |
| ALT (U/L) | 109.9 | 87.0 |
| Alkaline phosphatase (U/L) | 139.3 | 157.6 |
| IgG (mg/dL) | 1662.3 | 1595.2 |
| WBC (1000/μL)2 | 4.7 | 6.2 |
| Neutrophils (1000/μL) | 8.8 | 6.9 |
| Hemoglobin (g/dL) | 12.6 | 12.1 |
| Platelet (1000/ μL) | 214.1 | 195.7 |
| Number of IS | ||
| 0 | 10081 (100.0) | |
| 1 | 3326 (65.1) | |
| 2 | 1526 (29.9) | |
| 3+ | 254 (5.0) | |
- Citation: Rai K, Lindquist KJ, Kornak J, Ge J. Assessing the associations between immunosuppressant use and COVID-19 severity in patients with autoimmune hepatitis. World J Hepatol 2026; 18(2): 114481
- URL: https://www.wjgnet.com/1948-5182/full/v18/i2/114481.htm
- DOI: https://dx.doi.org/10.4254/wjh.v18.i2.114481